ZBP1 and head and neck squamous cell carcinoma: Clinically, ZBP1 expression could serve as a companion diagnostic to stratify patients for anti‐PD‐1/PD‐L1 immunotherapy, potentially enhancing response rates and personalising treatment strategies in HNSCC.